Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
Real-world incidence and risk of myelodysplastic syndrome and acute myeloid leukemia secondary to PARP inhibitors in ovarian cancer.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Corazón Villanueva Javier, González Pérez Cristina, Arenaza Peña Ainhoa, Marquina Gloria, Casado Herraez Antonio, Sánchez-Del Hoyo Rafael
Аннотация
PURPOSE: To analyze the association between myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) and PARP inhibitors (PARPi), to explore predisposing factors, and to evaluate their effectiveness and safety in clinical practice.
METHODS: Observational, analytical and retrospective study including patients with ovarian cancer treated with olaparib or niraparib from 2014 to 2024. Primary endpoint was to identify the incidence and risk factors of secondary malignancy, considering treatment duration, BRCA mutation, lines of platinum-based chemotherapy and grade 3-4 adverse events (AEs). Overall survival (OS), progression-free survival (PFS), and AEs were recorded.
RESULTS: Eighty patients were included. Six developed secondary MDS/AML, with an incidence of 11.6% (5/43) for olaparib and 2.7% (1/37) for niraparib. No significant correlation was found, except for hematological grade 3-4 AEs, associated with a higher risk of developing MDS/AML (OR: 32.3 p = 0.001). The median latency period was 8.8 months (1.5-102.2). For olaparib, median PFS was 37.8 months (95% CI 17.0-58.6); OS was not reached. For niraparib PFS was 10.0 months (95% CI 7.4-12.5), OS 25.1 months (95% CI 6.3-43.9). Grade 3-4 AEs occurred in 32.6% of olaparib and 35.2% of niraparib patients, mainly anemia and thrombocytopenia.
CONCLUSIONS: PARPi are effective and generally with a manageable safety profile. However, secondary MDS and AML, though rare, remain serious adverse events with incompletely defined risk factors. The observed incidence, particularly with olaparib, is comparable to or higher than that reported in trials, though the sample size was limited. Close monitoring of hematologic AEs may be key to preventing these neoplasms.
METHODS: Observational, analytical and retrospective study including patients with ovarian cancer treated with olaparib or niraparib from 2014 to 2024. Primary endpoint was to identify the incidence and risk factors of secondary malignancy, considering treatment duration, BRCA mutation, lines of platinum-based chemotherapy and grade 3-4 adverse events (AEs). Overall survival (OS), progression-free survival (PFS), and AEs were recorded.
RESULTS: Eighty patients were included. Six developed secondary MDS/AML, with an incidence of 11.6% (5/43) for olaparib and 2.7% (1/37) for niraparib. No significant correlation was found, except for hematological grade 3-4 AEs, associated with a higher risk of developing MDS/AML (OR: 32.3 p = 0.001). The median latency period was 8.8 months (1.5-102.2). For olaparib, median PFS was 37.8 months (95% CI 17.0-58.6); OS was not reached. For niraparib PFS was 10.0 months (95% CI 7.4-12.5), OS 25.1 months (95% CI 6.3-43.9). Grade 3-4 AEs occurred in 32.6% of olaparib and 35.2% of niraparib patients, mainly anemia and thrombocytopenia.
CONCLUSIONS: PARPi are effective and generally with a manageable safety profile. However, secondary MDS and AML, though rare, remain serious adverse events with incompletely defined risk factors. The observed incidence, particularly with olaparib, is comparable to or higher than that reported in trials, though the sample size was limited. Close monitoring of hematologic AEs may be key to preventing these neoplasms.